Track Your CD4 Count and Viral Load! Use TheBody.com's New Health Tracker!

HIV/AIDS Basics & Prevention

Just Diagnosed

HIV Treatment

Living With HIV

AIDS Policy & Activism

HIV Around the World

Conference Coverage

Rescriptor (Delavirdine)

The Basics | Research

See also: Medication Side Effects | Drug Interactions

Show Archived (Historical) Articles

Brand Name:	Rescriptor
Generic Name:	Delavirdine, DLV
Adult Single Dose:	Two 200-mg tablets (three times a day) OR four 100-mg tablets (three times a day)
Food & Liquid Restrictions:	None
Drug Class:	NNRTI

READ FIRST:

Delavirdine (Rescriptor) (May 18, 2008)
To read PDF, click here
From AIDS InfoNet
An Overview of Rescriptor (Delavirdine) (Regularly Updated)
To read PDF, click here
From U.S. National Institutes of Health

The Basics

Rescriptor (March/April 2009)
To read PDF, click here
In Positively Aware, from Test Positive Aware Network
Patient Information About Rescriptor (Delavirdine) (PDF) (May 2008)
From Pfizer, Inc.
Rescriptor (Delavirdine) (September 28, 2007)
Basic information on dosing schedules and side effects.
From U.S. Department of Veterans Affairs
Delavirdine (Rescriptor) (November 13, 2006)
From AIDSMeds.com

Research

Women and Pharmacology: Delavirdine Study (March 2001)
In Project Inform Perspective, from Project Inform

The Body is a service of Body Health Resources Corporation, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Body Health Resources Corporation, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.